Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IO103 |
Synonyms | |
Therapy Description |
IO103 is a peptide vaccine that targets CD274 (PD-L1), potentially resulting in an antitumor immune response and inhibition of tumor growth (PMID: 33671555) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IO103 | IO 103|IO-103 | IO103 is a peptide vaccine that targets CD274 (PD-L1), potentially resulting in an antitumor immune response and inhibition of tumor growth (PMID: 33671555) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04445064 | Phase II | IO102 IO103 | Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. (HN1901) | Unknown status | BEL | 0 |